Developing therapeutic monoclonal antibodies and ADC's is a key focus of the pharmaceutical industry's R&D. The European Antibody Congress 2012 bought together senior level executives and opinion leaders from around the globe to further their knowledge and engage in discussion on a variety of topics relating to mAbs, ADC's and bispecifics. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Dr David Szymkowski, Senior Director of Biotherapeutics, Xencor, âNovel formats for full-length bispecific antibodies'.
This presentation focuses on:
Â· Alternative immune models for conserved and post-translationally modified targets
Â· Insights into novel immune models via repertoire analysis
Â· Accelerating discovery of an optimal epitope early in a program for maximal impact
Are you interested in learning more and engaging in discussion on mAbs, ADC's, bispecifics and antibody biosimilars? Do you want to hear the most recent updates on mAbs/ADC's at the clinical stage? Do you want to network with senior executives and opinion leaders from truly international antibody pioneers? Take a look at the European Antibody Congress 2013.